Similar articles

• Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.

  Johnston SRD, Toi M, O'Shaughnessy J, Rastogi P, Campone M, Neven P, Huang CS, Huober J, Jaliffe GG, Cicin I, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, André V, Harbeck N, Martin M; monarchE Committee Members. Johnston SRD, et al. Lancet Oncol. 2023 Jan;24(1):77-90. doi: 10.1016/S1470-2045(22)00694-5. Epub 2022 Dec 6. Lancet Oncol. 2023. PMID: 36493792 Free PMC article. Clinical Trial.
• Erratum: Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.

  [No authors listed] [No authors listed] J Clin Oncol. 2024 Jun 10;42(17):2111. doi: 10.1200/JCO.24.00711. Epub 2024 Apr 30. J Clin Oncol. 2024. PMID: 38687953 Free PMC article. No abstract available.
• Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.

  Rastogi P, O'Shaughnessy J, Martin M, Boyle F, Cortes J, Rugo HS, Goetz MP, Hamilton EP, Huang CS, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, André V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Rastogi P, et al. J Clin Oncol. 2024 Mar 20;42(9):987-993. doi: 10.1200/JCO.23.01994. Epub 2024 Jan 9. J Clin Oncol. 2024. PMID: 38194616 Free PMC article.
• Role of abemaciclib in primary breast cancer: a narrative review of MonarchE.

  Takahashi N, Shimizu C, Shimomura A, Toi M. Takahashi N, et al. Transl Breast Cancer Res. 2022 Jan 31;3:3. doi: 10.21037/tbcr-21-27. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751527 Free PMC article. Review.
• Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence.

  Fung S, Blair HA. Fung S, et al. Target Oncol. 2023 Mar;18(2):287-294. doi: 10.1007/s11523-023-00952-y. Epub 2023 Feb 24. Target Oncol. 2023. PMID: 36826463 Review.